Advancing a Cutting-Edge Therapy for a Rare, Childhood Cancer

Paul Romness, president and CEO of OS Therapies, discusses why osteosarcomas have been difficult to treat, the company’s experimental therapy for the condition, and the promising results that have been seen to date.